We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Cancer Stem Cell Test Improves Survival of Patients with Deadly Brain Tumor

By LabMedica International staff writers
Posted on 09 May 2023
Print article
A study has found that ChemoID platform-predicted treatments led to longer survival (Photo courtesy of Freepik)
A study has found that ChemoID platform-predicted treatments led to longer survival (Photo courtesy of Freepik)

A new study has found that a cancer stem cell test can accurately determine more effective treatments, resulting in increased survival rates for patients with glioblastoma, a lethal brain tumor.

Researchers at The University of Cincinnati (Cincinnati, OH, USA) conducted a multi-institutional phase 3 clinical trial focusing on patients whose glioblastoma had recurred after initial treatment. They tested the efficacy of ChemoID, a CLIA and CAP-accredited diagnostic test developed by Cordgenics LLC (Huntington, WV, USA). Patients in the trial were randomized to either have their chemotherapy treatment chosen through ChemoID or have physicians select the chemotherapy using conventional methods. Patients whose treatments were determined using ChemoID experienced a significantly lower risk of death and survived, on average, 3.5 months longer than those in the physician-choice group.

As ChemoID concentrates on selecting treatments utilizing commercially available chemotherapies, this approach provides patients with more effective treatment at a reduced cost. The research team plans to seek funding to further develop ChemoID, potentially modifying the platform to include immunotherapy treatments or targeted therapies. Incorporating anti-cancer therapy that targets cancer stem cells earlier in the treatment plan could eliminate ineffective treatments, allowing patients to receive the maximum therapeutic benefit.

“ChemoID looks at cancer stem cells and their sensitivity to specified drugs to see which ones will work in a given cancer setting,” said Soma Sengupta, MD, PhD, a co-first author of the research and a University of Cincinnati Cancer Center physician-researcher. “We were pleasantly surprised that the ChemoID group did better and that a cancer stem cell-derived test is important in this disease. Where survival in recurrent glioblastoma is extremely poor, 3.5 months or more is wonderful. Some of my patients on this trial are still alive.”


Platinum Supplier
Xylazine Immunoassay Test
Xylazine ELISA
Gold Supplier
Blood Ammonia Test Analyzer
Complement 3 (C3) Test
GPP-100 C3 Kit
Flow Cytometry Software
iQue Forecyt

Print article


Clinical Chemistry

view channel
Image: A module with eight micro-devices, complete with microfluidic channels and drive motors (Photo courtesy of U.S Department of Energy)

Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses

Understanding the acidity or alkalinity of substances through pH measurement is crucial in many fields, from environmental monitoring to healthcare product safety. In many cases, these measurements must... Read more


view channel
Image: The QScout hematology analyzer has received US FDA 510(k) clearance (Photo courtesy of Ad Astra Diagnostics)

First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC

Sepsis, a critical medical condition that arises as an extreme response to infection, poses a significant health threat. It occurs when an infection triggers a widespread inflammatory response in the body.... Read more


view channel
Image: PointCheck is the world’s first device for non-invasive white cell monitoring (Photo courtesy of Leuko Labs)

World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw

One of the toughest challenges for cancer patients undergoing chemotherapy is experiencing a low count of white blood cells, also known as neutropenia. These cells play a crucial role in warding off infections.... Read more


view channel
Image: Current testing methods for antibiotic susceptibility rely on growing bacterial colonies in the presence of antibiotics (Photo courtesy of 123RF)

Rapid Antimicrobial Susceptibility Test Returns Results within 30 Minutes

In 2019, antimicrobial resistance (AMR) was responsible for the deaths of approximately 1.3 million individuals. The conventional approach for testing antimicrobial susceptibility involves cultivating... Read more


view channel
Image: AI methods used in satellite imaging can help researchers analyze tumor images (Photo courtesy of Karolinska Institutet)

AI Approach Combines Satellite Imaging and Ecology Techniques for Analysis of Tumor Tissue

Advancements in tumor imaging technology have significantly enhanced our ability to observe the minute details of tumors, but this also brings the challenge of interpreting vast amounts of data generated... Read more


view channel
Image: The acquisition significantly expands Medix Biochemica’s portfolio of IVD raw materials (Photo courtesy of ViroStat)

Medix Biochemica Acquires US-Based ViroStat to Expand Infectious Diseases Antibody Offering

Medix Biochemica (Espoo, Finland), a supplier of critical raw materials to the in vitro diagnostics (IVD) industry, has acquired ViroStat LLC (Portland, ME, USA), a provider of infectious disease antibodies... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.